Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroxyacetone for treatment of aluminum phosphide (rice tablet) poisoning
IRCT20180114038356N1Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Dihydroxyacetone in Aluminium phosphide poisoning, sponsored by Kerman University of Medical Sciences. Primary endpoints: Mortality prevention, Blood pressure and 1 more. Started May 2018; status: completed.
02
Drugs
Dihydroxyacetone
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on IRCT20180114038356N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180114038356N1.